GLPBio

WKYMVm

Catalog No.: GC16498Purity:>99.50%
COASDSData Sheet
WKYMVm, a synthetic peptide, is a potent Formyl peptide receptor 2 (FPR2) agonist, exerts an immunoregulatory effect.

Products are for research use only. Not for human use. We do not sell to patients.

WKYMVm
Cas No.: 187986-17-0
1mgIn Stock
$85.00
1
5mgIn Stock
$252.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

WKYMVm, a synthetic peptide, is a potent Formyl peptide receptor 2 (FPR2) agonist, exerts an immunoregulatory effect[1]. WKYMVm activates FPR2 to stimulate phagocytes, thereby inducing the chemotaxis and calcium ion influx of phagocytes[2]. WKYMVm has been widely used to promote the homing of endothelial colony-forming cells to stimulate ischemic angiogenesis[3].

In vitro, WKYMVm treatment (10μM) for 1 minute induced the translocation of p47phox and NADPH-dependent superoxide production in serum-deprived human fibroblasts[4]. Treatment with 10μM WKYMVm for 72 hours inhibited the formation of mature osteoclasts induced by RANKL in RAW264.7 cells and reduced the intracellular ROS levels[5]. Treatment with 5μM WKYMVm for 2 hours decreased the lipopolysaccharide (LPS) induced-production of inflammatory cytokines in rat microglial cells, and suppressed the activities of the ERK1/2 and NF-κB p65 signaling pathways[6].

In vivo, WKYMVm administration via subcutaneous injection (8mg/kg) every 2 days for 5 weeks ameliorated high-fat diet (HFD)-induced obesity in mice, reduced food intake, and alleviated HFD-induced histological damage in the liver and adipose tissues[7]. Subcutaneously inject WKYMVm (8mg/kg) once every 12 hours for a total of 60 hours to improved ulcerative colitis in mice triggered by dextran sulphate sodium salt (DSS)[8].

References:

[1] Ma H, Guo X, Wang Z, et al. Therapeutic potential of WKYMVm in diseases[J]. Frontiers in Pharmacology, 2022, 13: 986963.

[2] Le Y, Gong W, Li B, et al. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation[J]. The Journal of Immunology, 1999, 163(12): 6777-6784.

[3] Heo S C, Kwon Y W, Jang I H, et al. WKYMVm-induced activation of formyl peptide receptor 2 stimulates ischemic neovasculogenesis by promoting homing of endothelial colony-forming cells[J]. Stem cells, 2014, 32(3): 779-790.

[4] Ammendola R, Russo L, De Felice C, et al. Low-affinity receptor-mediated induction of superoxide by N-formyl-methionyl-leucyl-phenylalanine and WKYMVm in IMR90 human fibroblasts[J]. Free Radical Biology and Medicine, 2004, 36(2): 189-200.

[5] Hu J, Li X, Chen Y, et al. The protective effect of WKYMVm peptide on inflammatory osteolysis through regulating NF‐κB and CD9/gp130/STAT3 signalling pathway[J]. Journal of Cellular and Molecular Medicine, 2020, 24(2): 1893-1905.

[6] Zhang W, Chen J, Guo W, et al. WKYMVm/FPR2 alleviates spinal cord injury by attenuating the inflammatory response of microglia[J]. Mediators of inflammation, 2022, 2022(1): 4408099.

[7] Kang J H, Kim H S, Park S H, et al. WKYMVm ameliorates obesity by improving lipid metabolism and leptin signalling[J]. Journal of Cellular and Molecular Medicine, 2023, 27(18): 2782-2791.

[8] Kim S D, Kwon S, Lee S K, et al. The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis[J]. Experimental & molecular medicine, 2013, 45(9): e40-e40.

Protocol

Cell experiment [1]:

Cell lines

 Rat microglial cells

Preparation Method

 Rat microglial cells were cultured in DMEM-F12 medium supplemented with 10% fetal bovine serum, 100units/ml penicillin, and 100mg/ml streptomycin at 37°C with 5% ambient CO2. Cells were seeded at a density of 1×103 cells/well in 6-well plates overnight. Cells were treated with or without different concentrations of WKYMVm (0, 1, 2, and 5μM) for 2 hours, and then LPS was added into the culture media at 1μg/ml for 24h. Inflammatory cytokine production in the cells was measured.

Reaction Conditions

 0, 1, 2, and 5μM; 2h

Applications

 WKYMVm treatment reduced the LPS-induced levels of TNF-α, IL-6, and IL-1β within rat microglial cells in a dose-dependent manner.
Animal experiment [2]:

Animal models

 Male C57BL/6N mice

Preparation Method

Male C57BL/6N mice (8-week-old) were housed on a 12h light/dark cycle and had free access to food and water at 22°C. Mice were fed with a HFD (60% fat as kcal) for 6 or 10 weeks. After 4 weeks of HFD feeding, obese mice received subcutaneous injections of vehicle (distilled water) or WKYMVm (8mg/kg) once every 2 days. During the 5 weeks of injection, the body weight (g) and food intake (g/week) of the mice were recorded every week.

Dosage form

8mg/kg; once every 2 days; 5 weeks; s.c.

Applications

WKYMVm treatment markedly decreased food intake and attenuated weight gain in obese mice.

References:

[1] Zhang W, Chen J, Guo W, et al. WKYMVm/FPR2 alleviates spinal cord injury by attenuating the inflammatory response of microglia[J]. Mediators of inflammation, 2022, 2022(1): 4408099.

[2] Kang J H, Kim H S, Park S H, et al. WKYMVm ameliorates obesity by improving lipid metabolism and leptin signalling[J]. Journal of Cellular and Molecular Medicine, 2023, 27(18): 2782-2791.

Product Documents

Purity:>99.50%Appearance:A solid
COASDSData Sheet

Chemical Properties

CAS No.
187986-17-0
Chemical Name
(S)-6-amino-2-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-N-((5R,8S,11S,14S)-5-carbamoyl-15-(4-hydroxyphenyl)-8-isopropyl-11-(2-(methylthio)ethyl)-7,10,13-trioxo-2-thia-6,9,12-triazapentadecan-14-yl)hexanamide
SMILES
O=C([C@H](CCCCN)NC([C@H](CC1=CNC2=CC=CC=C12)N)=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(N)=O)CCSC)=O)C(C)C)=O)CCSC)=O)CC(C=C3)=CC=C3O
Molecular Formula
C41H61N9O7S2
Molecular Weight
856.11
Solubility
Soluble to 2 mg/ml in Water
Storage
-20°C, protect from light
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for WKYMVm

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%